[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100566781":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":39,"centralContacts":43,"locations":51,"responsibleParty":197,"collaborators":34,"id":199,"slug":34,"hasResults":200,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":206,"sex":207,"minAge":208,"maxAge":34,"enrollmentInfo":209,"targetDuration":34,"studyType":212,"phases":213,"briefSummary":216,"conditions":217,"keywords":219,"overallStatus":54,"whyStopped":34,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":236},{"fullName":5,"class":6},"Alnylam Pharmaceuticals","INDUSTRY",[8,14,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Part A: ALN-6400","EXPERIMENTAL","Participants will be administered a single dose of ALN-6400.",[13],"Drug: ALN-6400",{"label":15,"type":16,"description":17,"interventionNames":18},"Part A: Placebo","PLACEBO_COMPARATOR","Participants will be administered a single dose of placebo.",[19],"Drug: Placebo",{"label":21,"type":10,"description":22,"interventionNames":23},"Part B: ALN-6400","Participants will be administered multiple doses of ALN-6400.",[13],{"label":25,"type":16,"description":26,"interventionNames":27},"Part B: Placebo","Participants will be administered multiple doses of placebo.",[19],[29,35],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":34},"DRUG","ALN-6400","ALN-6400 will be administered subcutaneously (SC)",[9,21],null,{"type":30,"name":36,"description":37,"armGroupLabels":38,"otherNames":34},"Placebo","Placebo will be administered subcutaneously (SC)",[15,25],[40],{"name":41,"affiliation":5,"role":42},"Medical Director","STUDY_DIRECTOR",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":34,"email":48},"Alnylam Clinical Trial Information Line","CONTACT","1-877-ALNYLAM","clinicaltrials@alnylam.com",{"name":45,"role":46,"phone":50,"phoneExt":34,"email":48},"1-877-256-9526",[52,65,74,83,92,101,110,119,128,137,145,154,162,171,179,188],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":34},"Clinical Trial Site","RECRUITING","Birmingham","Alabama","35249","United States",{"type":60,"coordinates":61},"Point",[62,63],-86.80249,33.52066,{"lat":63,"lon":62},{"facility":53,"status":54,"city":66,"state":67,"zip":68,"country":58,"cosmosGeoPoint":69,"geoPoint":73,"contacts":34},"Cypress","California","90630",{"type":60,"coordinates":70},[71,72],-118.03729,33.81696,{"lat":72,"lon":71},{"facility":53,"status":54,"city":75,"state":76,"zip":77,"country":58,"cosmosGeoPoint":78,"geoPoint":82,"contacts":34},"Gainesville","Florida","32608",{"type":60,"coordinates":79},[80,81],-82.32483,29.65163,{"lat":81,"lon":80},{"facility":53,"status":54,"city":84,"state":85,"zip":86,"country":58,"cosmosGeoPoint":87,"geoPoint":91,"contacts":34},"Indianapolis","Indiana","46260",{"type":60,"coordinates":88},[89,90],-86.15804,39.76838,{"lat":90,"lon":89},{"facility":53,"status":54,"city":93,"state":94,"zip":95,"country":58,"cosmosGeoPoint":96,"geoPoint":100,"contacts":34},"Boston","Massachusetts","02114",{"type":60,"coordinates":97},[98,99],-71.05977,42.35843,{"lat":99,"lon":98},{"facility":53,"status":54,"city":102,"state":103,"zip":104,"country":58,"cosmosGeoPoint":105,"geoPoint":109,"contacts":34},"Rochester","Minnesota","55905",{"type":60,"coordinates":106},[107,108],-92.4699,44.02163,{"lat":108,"lon":107},{"facility":53,"status":54,"city":111,"state":112,"zip":113,"country":58,"cosmosGeoPoint":114,"geoPoint":118,"contacts":34},"St Louis","Missouri","63110",{"type":60,"coordinates":115},[116,117],-90.19789,38.62727,{"lat":117,"lon":116},{"facility":53,"status":54,"city":120,"state":121,"zip":122,"country":58,"cosmosGeoPoint":123,"geoPoint":127,"contacts":34},"Chapel Hill","North Carolina","27514",{"type":60,"coordinates":124},[125,126],-79.05584,35.9132,{"lat":126,"lon":125},{"facility":53,"status":54,"city":129,"state":34,"zip":130,"country":131,"cosmosGeoPoint":132,"geoPoint":136,"contacts":34},"Camperdown","2050","Australia",{"type":60,"coordinates":133},[134,135],151.17642,-33.88965,{"lat":135,"lon":134},{"facility":53,"status":54,"city":138,"state":34,"zip":139,"country":131,"cosmosGeoPoint":140,"geoPoint":144,"contacts":34},"Parkville","3050",{"type":60,"coordinates":141},[142,143],144.95,-37.78333,{"lat":143,"lon":142},{"facility":53,"status":54,"city":146,"state":34,"zip":147,"country":148,"cosmosGeoPoint":149,"geoPoint":153,"contacts":34},"Mount Royal","H3P 3P1","Canada",{"type":60,"coordinates":150},[151,152],-73.64918,45.51675,{"lat":152,"lon":151},{"facility":53,"status":54,"city":155,"state":34,"zip":156,"country":148,"cosmosGeoPoint":157,"geoPoint":161,"contacts":34},"Toronto","M5B 1W8",{"type":60,"coordinates":158},[159,160],-79.39864,43.70643,{"lat":160,"lon":159},{"facility":53,"status":54,"city":163,"state":34,"zip":164,"country":165,"cosmosGeoPoint":166,"geoPoint":170,"contacts":34},"Bordeaux","33000","France",{"type":60,"coordinates":167},[168,169],-0.58046,44.84124,{"lat":169,"lon":168},{"facility":53,"status":54,"city":172,"state":34,"zip":173,"country":165,"cosmosGeoPoint":174,"geoPoint":178,"contacts":34},"Bron","69500",{"type":60,"coordinates":175},[176,177],4.91303,45.73865,{"lat":177,"lon":176},{"facility":53,"status":54,"city":180,"state":34,"zip":181,"country":182,"cosmosGeoPoint":183,"geoPoint":187,"contacts":34},"Homburg","66421","Germany",{"type":60,"coordinates":184},[185,186],7.33867,49.32637,{"lat":186,"lon":185},{"facility":53,"status":54,"city":189,"state":34,"zip":190,"country":191,"cosmosGeoPoint":192,"geoPoint":196,"contacts":34},"L'Hospitalet de Llobregat","8907","Spain",{"type":60,"coordinates":193},[194,195],2.10028,41.35967,{"lat":195,"lon":194},{"type":198,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100566781",false,"NCT06659640","A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)","InsigHHT: A Phase 1\u002F2, Randomized, Double-blind, Placebo-controlled, 2-part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN-6400 in Adult Patients With Hereditary Hemorrhagic Telangiectasia (HHT)","InsigHHT","Inclusion Criteria -\n\nPart A:\n\n* Is a healthy adult volunteer\n\nPart B:\n\n* Is an adult patient with a clinical diagnosis of HHT\n\nExclusion Criteria -\n\nPart A:\n\n* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> upper limit of normal (ULN)\n* Has known human immunodeficiency virus (HIV) infection; or known current or chronic hepatitis C virus or hepatitis B virus infection\n* Has an estimated glomerular filtration (eGFR) of \\\u003C90 mL\u002Fmin\u002F1.73m\\^2 at screening\n\nPart B:\n\n* Has ALT or AST \\>2×ULN\n* Has total bilirubin \\>1.5×ULN\n* Has eGFR of \\\u003C30 mL\u002Fmin\u002F1.73m\\^2 at screening\n\nParts A and B:\n\n* Is not willing to comply with the contraceptive requirements during the study period\n\nNote: other protocol defined inclusion \u002F exclusion criteria apply",true,"ALL","18 Years",{"count":210,"type":211},120,"ESTIMATED","INTERVENTIONAL",[214,215],"PHASE1","PHASE2","The purpose of this study is to:\n\n* evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers\n* evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT",[218],"Hereditary Hemorrhagic Telangiectasia",[220,221,222,223,224,225,226],"siRNA","RNAi therapeutic","Plasminogen","PLG","HHT","Osler-Weber-Rendu","epistaxis","2026-06-10",{"date":229,"type":230},"2026-06-12","ACTUAL",{"date":232,"type":230},"2024-11-07",{"date":234,"type":211},"2028-06-22",{"name":5,"class":6},16]